Radiofrequency Ablation in Renal Cell Cancer: Review

Yüksel M, İpekçi T and Hoşcan MB

Department of Urology, Antalya Training and Research Hospital Antalya, Turkey
Department of Urology, Baskent University, Turkey
Department of Urology, Medstar Topçular Hospital, Turkey

^*Correspondance to: Mustafa Burak Ho?can 

 PDF  Full Text Mini Review | Open Access

Abstract:

Renal cell cancer is the most fatal urologic cancer which is diagnosed at the metastatic stage in 20- 30%. Generally small-sized renal masses are defined as slowly progressing masses with a size of ≤4 cm and have a good prognosis. As a result of the improvements in USG, CT and MRI technologies, incidental tumor determination ratio has increased in course of time. The gold standard treatment for small-sized renal masses is open/laparoscopic/robotic partial nephrectomy. RFA is a minimal invasive therapy method which is a good alternative to surgery in elder comorbid patients or the patients with genetic predisposition for multiple tumors or patients with bilateral tumors or patients with a solitary kidney. In this review we want to discuss technique, overall outcomes and complications of RFA and compare its efficacy with surgery and cryoablation according to the current literature. RFA is a good alternative treatment method for the RCC’s smaller than 4 cm with an oncologic efficiency closer to nephron protecting surgery and with lower complication ratios. More prospective randomized controlled studies are required in order to reveal the efficiency difference between cryoablation and RFA. We consider that in order to decrease the complication rates and to increase efficiency, making a good preoperative assessment and avoidance of RFA in central, renal tumors larger than 4 cm will be a rationalist approach.

Keywords:

Radiofrequency ablation; Kidney; Renal cell carcinoma; Complications

Cite the Article:

Yüksel M, ?pekçi T, Ho?can MB. Radiofrequency Ablation in Renal Cell Cancer: Review. Clin Oncol. 2016; 1: 1033.